RxDoctor Payments Data

Michael Jacobs, MD

Ophthalmology · Watkinsville, GANPI 1164495693

Payments from drug & device makers

$4,744in general payments, 2019–2025

Across 118 payments — averaging $40.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • AbbVie$425
  • Sun Pharmaceutical Industries Inc.$210
  • Novartis$189
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$154
  • Bausch & Lomb Americas Inc.$124
  • plus $299 from 8 others

What the payments were for

  • Food & beverage$4,744100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,744 in reported general payments places this provider in the 70th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$165,147
Medicare patients
619
Services billed
1,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine46$61,793
LumiganBimatoprost129$54,816
VyzultaLatanoprostene Bunod63$27,222
Cyclosporine22$18,312
TyrvayaVarenicline Tartrate19$17,729
Restasis MultidoseCyclosporine21$14,477
CombiganBrimonidine Tartrate/Timolol34$11,529
CequaCyclosporine11$10,173
RocklatanNetarsudil Mesylat/Latanoprost21$8,730
RhopressaNetarsudil Mesylate11$7,784
Latanoprost317$4,715
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat158$4,016
Timolol Maleate188$3,911
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$3,733
Lotemax SmLoteprednol Etabonate13$3,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Combigan$425$142,616230 claims
Bausch & Lomb Americas Inc.Vyzulta$124$27,22263 claims
Oyster Point Pharma, Inc.Tyrvaya$27$17,72919 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$74$16,51432 claims
Sun Pharmaceutical Industries Inc.Cequa$210$10,17311 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate$154$5,00424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Watkinsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →